Yüklüyor......
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
The objective of this study was to report our experience with weekly low-dose docetaxel (DOC) chemotherapy for patients with castration-resistant prostate cancer (CRPC). From 2007 to 2014, 39 consecutive patients received weekly low-dose DOC; the oncological effectiveness, side effects and tolerabil...
Kaydedildi:
| Yayımlandı: | Mol Clin Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4887800/ https://ncbi.nlm.nih.gov/pubmed/27284427 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.830 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|